Scotland reimburses bumper crop of new meds, rejects Cometriq
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium (SMC) has recommended seven products to be used on NHS Scotland, including Gilead's Harvoni (sofosbuvir and ledipasvir), GlaxoSmithKline's Tafinlar (dabrafenib), and two biosimilar versions of infliximab. However, the consortium rejected Exelixis/Swedish Orphan Biovitrum's rare disease drug Cometriq (cabozantinib).